The healthcare and biopharma industries are facing a growing talent crisis that threatens to slow innovation and place additional strain on already burdened systems. Within Canadian Health, workforce ...
The COVID-19 pandemic exposed critical vulnerabilities in global biopharma supply chains, disrupting the flow of raw materials, APIs, and finished therapies at an unprecedented scale. What was once op...
The digital health sector has experienced a dramatic rise over the past decade, fueled by venture capital, pandemic driven demand, and a wave of innovation promising to transform healthcare delivery. ...
The global biopharma industry is facing intensifying scrutiny over drug pricing as governments and payers push back against rising healthcare costs. In Canadian Health systems, where public funding pl...
For all the scientific advances in drug development, clinical trials remain one of the most inefficient and fragile components of the system. Patient recruitment is slow and costly, retention rates ar...
For decades, the pharmaceutical industry was built around the blockbuster model, developing medicines with broad indications capable of generating billions in annual revenue. These therapies, often de...
Canada’s biopharma sector is entering a defining phase where scientific ambition is increasingly intersecting with economic reality. Breakthroughs in gene therapies, precision medicine, and AI driven ...
Takeaways Bepirovirsen’s Canada filing signals a coming shift in the hepatitis B market from lifelong viral suppression to time‑limited “functional cure” regimens, which could reshape how p...
Takeaways: Dr. Reddy’s has become the first company to secure Health Canada approval for a generic semaglutide injection (Ozempic equivalent), with an NOC covering 2 mg and 4 mg once‑weekly pens...
Takeaways: Health Canada’s software update effectively turns MiniMed 780G into a more flexible, next‑gen automated insulin delivery platform in Canada, now covering adults with t...
